Tax-related stock sale by Solid Biosciences (SLDB) Chief Regulatory Officer

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported insider equity activity involving restricted stock units and related tax sales. On February 13, 2026, she acquired 8,125 shares of common stock through the exercise of restricted stock units at a price of $0.00 per share. On February 18, 2026, she sold 4,134 shares of common stock at a weighted average price of $5.8233 per share, with actual sale prices ranging from $5.23 to $6.14, to cover withholding taxes following RSU vesting under a pre-established automatic sell-to-cover instruction. After these transactions, she held 74,318 shares of common stock and 16,250 restricted stock units.

Insider Trade Summary

Net Seller: 4,134 shares ($24,074)

Net Sell 3 txns

Insider Hanrahan Jessie

Role Chief Regulatory Officer

Sold 4,134 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,134	$5.8233	$24K
Exercise	Restricted Stock Units	8,125	$0.00	--
Exercise	Common Stock	8,125	$0.00	--

Holdings After Transaction: Common Stock — 74,318 shares (Direct); Restricted Stock Units — 16,250 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanrahan Jessie

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		8,125	A	(1)	78,452	D
Common Stock	02/18/2026		S		4,134(2)	D	$5.8233(3)	74,318	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			8,125	(4)	(4)	Common Stock	8,125	$0.00	16,250	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

4. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did SLDB Chief Regulatory Officer Jessie Hanrahan report?

Jessie Hanrahan reported both an RSU exercise and a related share sale. She exercised 8,125 restricted stock units into common stock at $0.00 per share, then sold 4,134 common shares at a weighted average price of $5.8233 to cover tax withholding obligations.

How many Solid Biosciences (SLDB) shares did Jessie Hanrahan sell and at what price?

She sold 4,134 shares of Solid Biosciences common stock. The weighted average sale price was $5.8233 per share, with individual trades executed between $5.23 and $6.14, according to the weighted average pricing disclosure.

Was the SLDB insider sale by Jessie Hanrahan a discretionary trade?

The sale was not a discretionary trade by Jessie Hanrahan. It was executed to cover withholding taxes after RSUs vested, under a durable automatic sales instruction letter effecting a sell-to-cover election previously adopted by her on August 16, 2024.

What are the terms of Jessie Hanrahan’s restricted stock units at Solid Biosciences (SLDB)?

The restricted stock units were granted on February 13, 2024. They vest over four years, with 25% of the original number of shares vesting on each anniversary of the grant date until the fourth anniversary, subject to continued service conditions.

How many Solid Biosciences (SLDB) shares and RSUs does Jessie Hanrahan hold after these transactions?

After the reported transactions, she held 74,318 common shares. She also beneficially owned 16,250 restricted stock units, each representing a contingent right to receive one additional share of Solid Biosciences common stock upon vesting and settlement.

What type of insider transaction code was used in the SLDB Form 4 for Jessie Hanrahan?

The Form 4 shows codes M and S for Hanrahan’s activity. Code M reflects the exercise or conversion of derivative securities (restricted stock units), while code S reflects an open-market or private sale of common shares to satisfy tax withholding obligations.